Background: Invasive mucormycosis (IM) poses a substantial morbidity and mortality burden among immunocompromised patients. Objectives: We aim to compare the real-world effectiveness and safety of isavuconazole with those of amphotericin B in patients with IM. Patients and methods: In this observational cohort study, we enrolled patients who were diagnosed with IM and treated with either isavuconazole or amphotericin B. Results: A total of 106 patients met the study criteria. Of these, 47 received isavuconazole, and 59 received amphotericin B as the primary treatment. The two cohorts had similar baseline characteristics, including a history of malignancy, use of immunosuppressants, infection sites, and pathogens. The amphotericin B group demonstrated a significantly greater incidence of renal disorders (p < 0.001) and hypokalemia (p < 0.001) than the isavuconazole group. The proportion of patients who received salvage therapy was greater in the amphotericin B group than in the isavuconazole group (42% vs. 6%, p < 0.001). Eighteen patients in the amphotericin B group discontinued treatment because of adverse events, whereas no patients in the isavuconazole group discontinued treatment because of adverse events. A significant difference in the primary therapeutic response between the isavuconazole and amphotericin B groups was noted (p = 0.013), with a higher treatment failure rate in the amphotericin B group (68% vs. 36%, p = 0.001). However, there were no significant differences in all-cause mortality or mucormycosis-attributable mortality rates between the two groups. Conclusions: Isavuconazole outperformed amphotericin B as a first-line treatment option for IM in terms of its clinical effectiveness and safety.

Taeniasis and cysticercosis, which are caused by Taenia saginata, Taenia solium and Taenia asiatica, are zoonotic parasitic infections with a significant disease burden worldwide. There is consensus amongst experts that T. saginata is a common tapeworm that causes taeniasis in humans as opposed to cysticercosis. This case study of a middle-aged Tibetan man conducted in 2021 challenges the prevailing notion that T. saginata exclusively causes taeniasis and not cysticercosis by documenting symptoms and laboratory studies related to both taeniasis and multiple cysticercosis. The patient's medical record with the symptoms of taeniasis and cysticercosis was reviewed, and the tapeworm's proglottids and cyst were identified from the patient by morphological evaluation, DNA amplification and sequencing. The patient frequently experienced severe headaches and vomiting. Both routine blood screenings and testing for antibodies against the most common parasites were normal. After anthelmintic treatment, an adult tapeworm was found in feces, and medical imaging examinations suggested multiple focal nodules in the brain and muscles of the patient. The morphological and molecular diagnosis of the proglottids revealed the Cestoda was T. saginata. Despite the challenges presented by the cyst's morphology, the molecular analysis suggested that it was most likely T. saginata. This case study suggests that T. saginata infection in humans has the potential to cause human cysticercosis. However, such a conclusion needs to be vetted by accurate genome-wide analysis in patients with T. saginata taeniasis associated with cysts. Such studies shall provide new insights into the pathogenicity of T. saginata.

Rationale: The clinical manifestations in patients with disseminated tuberculosis (TB) are nonspecific and may present challenges for early diagnosis. Patient concerns and diagnoses: We describe the case of a 44-year-old man who presented with abdominal pain and discomfort for more than a month. He had undergone surgery for a chest wall abscess 9 months ago. Computed tomography scans showed a miliary pattern in the lung and multiple abscesses in the liver, spleen, left psoas major muscle, skin, and soft tissue, with rim enhancement. Mycobacterium tuberculosis was detected in the drainage fluid of the abscesses and surgical slices, and disseminated TB was diagnosed. Interventions and outcomes: With anti-tuberculosis therapy, the abscesses were gradually absorbed and all cultures were negative. Lessons: The patient exemplifies the difficulty of the early diagnosis of disseminated TB. Disseminated TB should be considered first in patients with multisystem illness, and then evidence should be pursued relentlessly to establish a diagnosis.

Mucormycosis, an aggressive fungal infection caused by members of the order Mucorales , progresses rapidly and is associated with high mortality, particularly in immunocompromised hosts such as patients with uncontrolled diabetes, transplant recipients or those with COVID‐19‐associated immunosuppression. Early diagnosis remains challenging with current clinical methods, yet it is essential to reduce mortality. This review examines the evolution of diagnostic strategies for mucormycosis, ranging from conventional techniques such as histopathology, culture and microscopy to advanced and emerging methods including molecular assays, serological testing, imaging and metabolomics. We also explore the ongoing transition towards integrated, rapid and non‐invasive diagnostic platforms that leverage novel biomarkers, portable devices and artificial intelligence. These new technologies have the potential to facilitate early diagnosis, thereby enabling early treatment and reducing the mortality rate of mucormycosis.

Coxsackievirus B3 (CVB3) is one of the major viruses associated with human viral myocarditis, in members of the Picornaviridae order. Cellular localization depends on the activity of nuclear pore complexes, which are composed of nucleoporins (Nups), including Nup62. To better understand interactions between Nup62 and CVB3, we investigated the impact of CVB3 infection on Nup62 levels and the impact of Nup62 production on CVB3 replication in cultured cells. We found that CVB3 infection correlated with decreased Nup62 expression in vitro and that lower levels of Nup62 led to inhibition of CVB3 replication and to decreased activation of AKT and extracellular signal-related kinase. Our study reveals that Nup62 regulates the CVB3 replication during infection.

The risk factors and prognosis of polymyxin- and carbapenem-resistant Enterobacteriaceae (PR-CRE) infections were analyzed to reduce their incidence and concurrently improve patient prognosis. This retrospective study analyzed patients with CRE infections admitted to West China Hospital of Sichuan University between 1 September 2019 and 30 September 2023. Based on polymyxin susceptibility, the cases were categorized into PR-CRE and PS-CRE (polymyxin-susceptible CRE) groups, with 1:1 propensity score matching performed between the two cohorts. Comprehensive data, including demographic characteristics, laboratory findings, antibiotic regimens, and clinical outcomes, were collected and analyzed to identify risk factors for PR-CRE infections and evaluate treatment efficacy. This study aims to provide evidence-based references for infection control strategies and antimicrobial stewardship in managing PR-CRE infections. A total of 254 patients were included in this study, with 127 patients in the PR-CRE group. The sensitivity rates of isolates in the PR-CRE group to tigecycline and ceftazidime–avibactam were 94.4% and 88.9%, respectively. Multivariate analysis identified chronic organic disease (OR 2.747, 95% CI 1.303–5.789; p = 0.008) and the use of polymyxin ≥ 3 days (OR 19.203, 95% CI 7.126–51.752; p < 0.001) as independent risk factors for PR-CRE infection. Moreover, ceftazidime–avibactam-based regimens were superior to tigecycline-based regimens for the treatment of PR-CRE infections (71.43% vs. 58.46%), especially in critically ill patients (33.33% vs. 58.82%). Finally, a SOFA score ≥ 5.5 (HR 6.718, 95% CI 2.526–17.866; p < 0.001) was identified as an independent risk factor for 28-day mortality in patients with PR-CRE infection. The presence of chronic organic diseases and the use of polymyxin for ≥3 days were identified as independent risk factors associated with PR-CRE infections in hospitalized patients, highlighting the need to optimize polymyxin use. Furthermore, the efficacy of ceftazidime–avibactam-based regimens may be superior to tigecycline-based regimens for the treatment of PR-CRE infections.